Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee

Serum Bupivacaine Concentration Levels After Injection of the Knee Joint With a Mixture of Liposomal Bupivacaine and Free Bupivacaine During Total Knee Arthroplasty

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02626559

Enrollment

Registered

2015-12-10

Start date

2015-11-30

Completion date

2016-11-30

Last updated

2016-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Local

Brief summary

Serum levels of bupivacaine over time after peri-articular injection of a mixture of liposomal bupivacaine and plain bupivacaine during total knee arthroplasty.

Interventions

DRUGliposomal bupivacaine/plain bupivacaine peri-articular injection

Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults of at least 18 years of age having a primary, unilateral total knee arthroplasty with a surgical plan to have an intra-articular injection of a mixture of 266 mg of Exparel, 125 mg of bupivacaine, 1:300,000 epinephrine, and 0.9% saline to make a total volume of 100 ml.

Exclusion criteria

* Known hepatic dysfunction or renal insufficiency (creatinine \> 1.5 mg/dL); * allergy to the study medications; * pregnancy; * incarceration; * inability to communicate with the investigators; * morbid obesity (body mass index \> 40 kg/m2).

Design outcomes

Primary

Measure	Time frame
Serum Bupivacaine levels	5 minutes to 24 hours after injection

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026